Search our Database of Scientific Publications and Authors

I’m looking for a

    29939 results match your criteria Graft Versus Host Disease

    1 OF 599

    The Emerging Link Between the Complement Cascade and Purinergic Signaling in Stress Hematopoiesis.
    Front Immunol 2018 5;9:1295. Epub 2018 Jun 5.
    Department of Hematology Warsaw Medical University, Warsaw, Poland.
    Innate immunity plays an important role in orchestrating the immune response, and the complement cascade (ComC) is a major component of this ancient defense system, which is activated by the classical-, alternative-, or mannan-binding lectin (MBL) pathways. However, the MBL-dependent ComC-activation pathway has been somewhat underappreciated for many years; recent evidence indicates that it plays a crucial role in regulating the trafficking of hematopoietic stem/progenitor cells (HSPCs) by promoting their egress from bone marrow (BM) into peripheral blood (PB). This process is initiated by the release of danger-associated molecular patterns (DAMPs) from BM cells, including the most abundant member of this family, adenosine triphosphate (ATP). Read More

    Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand.
    Eye (Lond) 2018 Jun 19. Epub 2018 Jun 19.
    Prince of Wales Clinical School, University of New South Wales, High Street, Randwick, Sydney, NSW, 2031, Australia.
    Aims: This study aimed to determine the incidence, clinical features and management of cicatrising conjunctivitis in Australia and New Zealand, also enabling comparison with data from the United Kingdom.

    Methods: A prospective surveillance study was conducted over 17 months via the Australian and New Zealand Ophthalmic Surveillance Unit with a one-year follow-up period. Practicing ophthalmologists on the Surveillance Unit's database were asked to report recently diagnosed cases of cicatrising conjunctivitis on a monthly basis. Read More

    TTC7A mutation must be considered in patients with repeated intestinal atresia associated with early inflammatory bowel disease: Two new case reports and a literature review.
    Arch Pediatr 2018 Jun 16. Epub 2018 Jun 16.
    Department of Pediatric Hepatology Gastroenterology and Nutrition, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant de Lyon, 69677 Bron, France; Inserm U1060, laboratoire CarMeN, université Claude-Bernard Lyon 1, 69008 Lyon, France. Electronic address:
    TTC7A mutations cause multiple neonatal intestinal atresias with early inflammatory bowel disease and severe combined immunodeficiency. There are no treatment protocols for this rare disease. Two new cases are described for which radical early treatment measures - total enterectomy, home parenteral nutrition, immunoglobulin therapy and intravenous antibiotic prophylaxis - have allowed both patients to develop optimally. Read More

    Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.
    Gastroenterology Res 2018 Jun 31;11(3):174-188. Epub 2018 May 31.
    Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
    An increasing number of drugs including monoclonal antibodies and small molecules, either anti-inflammatory or immunity-enhancing, have been developed to treat human diseases and the number of medications in these classes is likely to expand in the future. The two most commonly used categories of such therapies are the anti-inflammatory group (anti- tumor necrosis factor (TNF) α, anti-interleukins/interleukin receptors, and anti-integrin bodies) and the anti-tumoral agents (immune checkpoint inhibitors, anti-CD20, and anti-endothelial growth factor). Although the anti-inflammatory biologics have brought about a revolutionary effect in the management of a variety of autoimmune disorders including rheumatologic diseases, inflammatory bowel disease, and inflammatory dermatological diseases, their ability to induce colitis in patients without a prior history of colitis or exacerbate quiescent colitis has been increasingly and unexpectedly recognized. Read More

    Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients.
    Bone Marrow Transplant 2018 Jun 18. Epub 2018 Jun 18.
    Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
    Fludarabine is used as a common component of conditioning regimens for haematopoietic stem cell transplantation (HSCT). However, knowledge regarding the pharmacokinetic characteristics of once-daily fludarabine dosing in children is limited. This study investigated the pharmacokinetics of fludarabine and evaluated its associations with clinical outcomes in paediatric patients. Read More

    Co-expression analysis reveals key gene modules and pathways of oral squamous cell carcinoma.
    Cancer Biomark 2018 Jun 6. Epub 2018 Jun 6.
    Department of Stomatology, Hubei Women's and Children's Hospital, Wuhan, Hubei, China.
    Background: Oral squamous cell carcinoma is a malignant tumor which is particularly common in the developing world, mostly in older males.

    Objective: Although gene expression analyses had been performed previously, to our best knowledge, systemic co-expression analysis for this disease is still lacking to date.

    Methods: In this study, we built the co-expression modules with the help of Weighted Correlation Network Analysis (WGCNA) and investigated the function enrichment of co-expression genes from important modules by bioinformatics analysis. Read More

    Regulatory T cells from allo- to xenotransplantation: Opportunities and challenges.
    Xenotransplantation 2018 05;25(3):e12415
    Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
    Regulatory T cells (Treg) are currently being evaluated in clinical allotransplantation for tolerance induction, with proven safety in humans with autoimmune diseases and graft-versus-host disease. A considerable amount of recent data suggests that additional factors may need to be validated, including the stability and commitment of newly discovered Treg subsets under inflammatory conditions, to further warrant safe and effective Treg-based therapeutic approaches. This review explores the opportunities and challenges of Treg-based cell therapy in xenotransplantation. Read More

    Cincinnati Protocol for Preoperative Screening and Donor Selection for Ocular Surface Stem Cell Transplantation.
    Cornea 2018 Jun 14. Epub 2018 Jun 14.
    Cincinnati Eye Institute, University of Cincinnati, Department of Ophthalmology, Cincinnati, OH.
    Purpose: To describe our process for preoperative screening and donor selection for ocular surface stem cell transplantation (OSST).

    Methods: A 7-year retrospective chart review was performed on limbal stem cell deficiency patients. The inclusion criterion was all patients who underwent an OSST procedure. Read More

    Evans Syndrome After Successful Immunosuppressant-Free Living-Donor Liver Transplant.
    Exp Clin Transplant 2018 Jun 18. Epub 2018 Jun 18.
    From the Hepato-Biliary-Pancreatic Surgery and Transplantation Department, Kyoto University, Kyoto, Japan; and the General Surgery Department, Alexandria University, Alexandria, Egypt.
    Evans syndrome is an uncommon disease characterized by a combination of autoimmune hemolytic anemia and autoimmune thrombocytopenia concomitantly or sequentially with a positive direct Coombs test in the absence of any underlying known cause. Here, we present a case of an adult patient who underwent living-donor liver transplant that was preceded by bone marrow transplant 20 years earlier from the same HLA identical donor and who received a single-agent immunosuppressive therapy for only 2 months as prophylaxis against graft-versus-host disease. Two months after transplant, he developed Evans syndrome with severe anemia and thrombocytopenia. Read More

    Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
    Drugs Today (Barc) 2018 May;54(5):305-313
    Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, California, USA.
    Chronic graft-versus-host disease (cGvHD) is a grave complication of allogeneic hematopoietic cell transplantation (alloHCT). Despite the use of prophylactic regimens for cGvHD, a significant proportion of patients develop cGvHD following alloHCT. The standard first-line therapy for cGvHD is high-dose corticosteroids. Read More

    Targeting Inflammatory T Helper Cells Retinoic Acid-Related Orphan Receptor Gamma t Is Ineffective to Prevent Allo-Response-Driven Colitis.
    Front Immunol 2018 25;9:1138. Epub 2018 May 25.
    Department of Medicine 1, University Hospital Erlangen, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research, Erlangen, Germany.
    Intestinal graft-versus-host disease (GvHD) is a life-threatening, inflammatory donor T cell-mediated complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the light of the reported efficacy of interleukin-23 (IL-23)-blockade to mitigate syngeneic intestinal inflammation in inflammatory bowel disease patients, targeting IL-23 and thereby interleukin-17a (IL-17a) producing T helper (Th17) cells as the T cell subset assumed to be mostly regulated by IL-23, has emerged as a putatively general concept to harness immune-mediated mucosal inflammation irrespective of the underlying trigger. However, the role of Th17 cells during allo-response driven colitis remains ambiguous due to a series of studies with inconclusive results. Read More

    Gastrointestinal graft-versus-host disease is a risk factor for post-engraftment blood stream infection in allogeneic hematopoietic stem cell transplant recipients.
    Biol Blood Marrow Transplant 2018 Jun 14. Epub 2018 Jun 14.
    Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan. Electronic address:
    Bloodstream infection (BSI) is a well-known cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Here, we conducted a retrospective study to assess the morbidity, etiology, risk factors, and outcomes of BSI in the post-engraftment period (PE-BSI) following allo-HSCT. Forty-three out of 316 patients (13. Read More

    Hematogones predict better outcome in allogeneic hematopoietic stem cell transplantation irrespective of graft sources.
    Biol Blood Marrow Transplant 2018 Jun 14. Epub 2018 Jun 14.
    Department of Hematology, Hokkaido University Faculty of Medicine.
    Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients undergone allo-HSCT, which was the largest population-based cohort reported so far. Read More

    Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies.
    Biol Blood Marrow Transplant 2018 Jun 13. Epub 2018 Jun 13.
    Department of Pediatrics, University of Arizona, Tucson, Arizona; University of Arizona Cancer Center, Tucson, Arizona; University of Arizona, Arizona and Banner University Medical Center, Tucson, Arizona.
    More than half of patients undergoing hematopoietic cell transplantation at our institution are ethnic or racial minorities, making the search for matched unrelated donors more challenging. Since the introduction of haploidentical bone marrow transplant (haplo-BMT) into our pediatric BMT program in 2015, 69.2% of the recipients have been minorities. Read More

    Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
    Leukemia 2018 Jun 15. Epub 2018 Jun 15.
    Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer and Sackler Medical School, Tel-Aviv University, Tel-Aviv, Israel.
    Haploidentical stem cell transplantation with T cell-replete grafts and post-transplant cyclophosphamide (PTCy) is increasingly used with encouraging outcome. Natural killer (NK) cell alloreactivity, predicted by missing killer cell immunoglobulin-like receptor (KIR) ligands in the recipient that are present in their donor improves outcome of T cell-depleted haploidentical transplants. We explored the role of KIR ligand mismatching in 444 acute leukemia patients after T cell-replete transplants with PTCy. Read More


    Characterization of monocyte subtypes regarding their phenotype and development in the context of graft-versus-host disease.
    Transpl Immunol 2018 Jun 12. Epub 2018 Jun 12.
    Children's Hospital, University of Tuebingen, Germany. Electronic address:
    Graft-versus-host disease (GvHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). In this study, monocyte subtypes were characterized regarding cytokine expression pattern and development in the context of GvHD. Using inflammatory S100 proteins for monocyte stimulation, it could be demonstrated that intermediate monocytes are the main producers of inflammatory cytokines such as IL-6 and TNFα known to be involved in the development of Th17 cells pointing towards an inflammatory phenotype of this monocyte subtype. Read More

    The eGVHD App has the potential to improve the accuracy of graft versus host disease assessment: a multicenter randomized controlled trial.
    Haematologica 2018 Jun 14. Epub 2018 Jun 14.
    Academic Centre for Nursing and Midwifery, KU LEUVEN, Leuven, Belgium.
    Graft-versus-host disease assessment has been shown to be a challenge for healthcare professionals, leading to the development of the eGVHD App (www.uzleuven.be/egvhd). Read More

    Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor- a multicenter analysis.
    Am J Transplant 2018 Jun 13. Epub 2018 Jun 13.
    Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
    Tolerance induction through simultaneous hematopoietic stem cell- and renal transplantation has shown promising results, but it is hampered by the toxicity of preconditioning therapies and graft-versus-host disease. Moreover, renal function has never been compared to conventionally transplanted patients, thus, whether donor-specific tolerance results in improved outcomes remains unanswered. We collected follow-up data of published cases of renal transplantations after hematopoietic stem cell transplantation from the same donor and compared patient- and transplant kidney survival- as well as function with caliper-matched living-donor renal transplantations from the Austrian dialysis and transplant registry. Read More

    Transfusion Medicine and Molecular Genetic Methods.
    Int J Prev Med 2018 16;9:45. Epub 2018 May 16.
    School of Health Sciences, Health Campus, Universiti Sains Malaysia, Kelantan, Malaysia.
    Transfusion procedures are always complicated by potential genetic mismatching between donor and recipient. Compatibility is determined by several major antigens, such as the ABO and Rhesus blood groups. Matching for other blood groups (Kell, Kidd, Duffy, and MNS), human platelet antigens, and human leukocyte antigens (HLAs) also contributes toward the successful transfusion outcomes, especially in multitransfused or highly immunized patients. Read More

    Colonic graft-vs.-host disease in autologous versus allogeneic transplant patients: earlier onset, more apoptosis, and lack of regulatory T-cell attenuation.
    Mod Pathol 2018 Jun 13. Epub 2018 Jun 13.
    Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
    Histologic characterization of graft-vs.-host disease in autologous stem cell transplant patients has been limited. The aims of this study were to characterize colonic graft-vs. Read More

    Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases.
    Nat Rev Nephrol 2018 Jun 12. Epub 2018 Jun 12.
    CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences/Shanghai Jiao Tong University School of Medicine, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
    Mesenchymal stem cells (MSCs; also referred to as mesenchymal stromal cells) have attracted much attention for their ability to regulate inflammatory processes. Their therapeutic potential is currently being investigated in various degenerative and inflammatory disorders such as Crohn's disease, graft-versus-host disease, diabetic nephropathy and organ fibrosis. The mechanisms by which MSCs exert their therapeutic effects are multifaceted, but in general, these cells are thought to enable damaged tissues to form a balanced inflammatory and regenerative microenvironment in the presence of vigorous inflammation. Read More

    Hepatic veno-occlusive disease following sirolimus-based immune suppression.
    Bone Marrow Transplant 2018 Jun 12. Epub 2018 Jun 12.
    BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
    Sirolimus-based graft vs. host disease (GVHD) prophylaxis is associated with higher incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after allogeneic hematopoietic cell transplantation (HCT). However, whether the clinical manifestations and prognosis of VOD/SOS differs when diagnosed in the setting of sirolimus-based GVHD prophylaxis is not well studied. Read More

    Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.
    Oral Oncol 2018 Jun 10;81:1-9. Epub 2018 Apr 10.
    Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, USA.
    Objectives: Secondary oral squamous cell carcinoma (OSCC) is a late complication in allogeneic hematopoietic stem cell transplantation (HSCT) patients, but little is known about long-term outcomes and prognostication. Additionally, molecular alterations and immunologic insights unique to this disease remain largely unexplored.

    Methods: We present a cohort of 31 patients with post-HSCT OSCC and reported on clinicopathologic predictors of survival. Read More

    The importance of topical steroids after adhesiolysis in erosive lichen planus and graft versus host disease.
    J Obstet Gynaecol 2018 Jun 8:1-4. Epub 2018 Jun 8.
    a Department of Gynaecological Oncology , Guy's and St Thomas NHS Trust , London , UK.
    The aim of this study was to assess the efficacy of a postoperative steroid regimen in maintaining vulvovaginal architecture and vaginal patency following surgical adhesiolysis in severe erosive lichen planus (ELP) and genital graft versus host disease (GVHD). Sixteen women applied potent topical steroids to the vulva and vagina from 48 hours after surgery. Sexual and urinary function and vulvovaginal anatomy were assessed at 6 weeks, 6, 12 and 24 months. Read More

    A Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-Versus-Host Disease.
    Biol Blood Marrow Transplant 2018 Jun 5. Epub 2018 Jun 5.
    National Cancer Centre Singapore, 11 Hospital Drive, 169610. Electronic address:
    The immunosuppressive properties of mesenchymal stromal cells (MSCs) have been clinically proven to be effective in treating graft-versus-host disease (GVHD). However, MSC therapy is limited by the need for laborious and expensive manufacturing processes that are fraught with batch-to-batch variability. Substitution of MSC therapy with key MSC-mediated immunomodulatory factors could be an option for GVHD treatment. Read More

    Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study.
    Clin Exp Dermatol 2018 Jun 7. Epub 2018 Jun 7.
    Department of Dermatology, Christian Medical College, Vellore, Tamil Nadu, India.
    Background: The skin is the most common organ involved in acute graft-versus-host disease (GvHD). Because histopathology has limited utility in ruling out clinical mimics of acute skin GvHD, more accurate diagnostic techniques are required.

    Aim: To evaluate the utility of elafin expression in skin by immunohistochemistry (IHC) for accurate diagnosis of acute skin GvHD. Read More

    Red blood cells metabolome changes upon treatment with different X-ray irradiation doses.
    Ann Hematol 2018 Jun 7. Epub 2018 Jun 7.
    Transfusion Medicine Unit, AUSL-IRCCS, Reggio Emilia, Italy.
    The upholding of red blood cells (RBC) quality and the removal of leukocytes are two essential issues in transfusion therapy. Leukodepletion provides optimum results, nonetheless there are cases where irradiation is recommended for some groups of hematological patients such as the ones with chronic graft-vs-host disease, congenital cellular immunodeficiency, and hematopoietic stem cell transplant recipients. The European guidelines suggest irradiation doses from 25 to 50 Gray (Gγ). Read More

    Congenital intestinal atresias with multiple episodes of sepsis: A case report and review of literature.
    Medicine (Baltimore) 2018 Jun;97(23):e10939
    Neonatal Unit, Department of Pediatrics, IDIS, CIBERER.
    Introduction: Hereditary multiple intestinal atresia associated with severe combined immunodeficiency (MIA-SCID) is a very rare disease caused by deleterious mutations in the tetratricopeptide repeat domain-containing protein 7A gene TTC7A. It is characterized by intestinal obstruction, sepsis, and a poor prognosis. Insights into phenotype-genotype correlations could help to guide genetic counseling and increase our knowledge of the natural history of this disease. Read More

    Dermatologic considerations in pediatric transplant recipients.
    Curr Opin Pediatr 2018 Jun 6. Epub 2018 Jun 6.
    Division of Dermatology, Departments of Medicine and Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
    Purpose Of Review: The pediatric transplant patient population is growing as the number of solid organ transplants and indications for hematopoietic stem cell transplant increase. Understanding cutaneous sequelae of pediatric transplant and treatment strategies to manage these outcomes is vital to the care of these patients.

    Recent Findings: Important work in the past year enhances our understanding of the cutaneous implications of pediatric transplantation, including further work in areas of malignancy, infection, and graft versus host disease as well as newly reported risks. Read More

    [Molecular-targeted therapy and its impact on post-transplant immunity].
    Rinsho Ketsueki 2018 ;59(5):557-565
    Hematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital.
    Over the past few decades, the advancements in the area of molecular-targeted therapy have revolutionized the treatment of hematological malignancies, thereby altering the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT continues to play an essential role in the treatment of hematological malignancies because the cure is rare by targeted therapy alone. In the modern era, the incorporation of molecular-targeted therapy, including chemotherapy and allo-HSCT, into the conventional therapy is the key to attaining therapeutic success. Read More

    [Chronic graft-versus-host disease: diagnosis and treatment].
    Rinsho Ketsueki 2018 ;59(5):549-556
    Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital.
    Chronic graft-versus-host disease (cGVHD) occurs in approximately 40% of patients who undergo allogeneic hematopoietic cell transplantation. It affects various organs and causes significant morbidity and mortality. The manifestations of cGVHD resemble those of autoimmune diseases. Read More

    [Acute graft-versus-host disease: diagnosis and treatment].
    Rinsho Ketsueki 2018 ;59(5):540-548
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine.
    Acute graft-versus-host disease (GVHD) is diagnosed by the presence of, at least, one of the skin, liver, and gut damage and the absence of a disease similar to it. Except upper gastrointestinal GVHD, acute GVHD is diagnosed on the basis of clinical findings. The diagnosis via biopsy does not necessarily coincide with the clinical diagnosis of acute GVHD. Read More

    [Successful treatment of secondary graft failure in a mixed-phenotype acute leukemia patient with haploidentical hematopoietic stem cell transplantation and post-transplant cyclophosphamide administration].
    Rinsho Ketsueki 2018 ;59(5):485-488
    Department of Medical Oncology and Hematology, Oita University Faculty of Medicine.
    A 38-year-old woman in the first remission of mixed-phenotype acute leukemia underwent unrelated bone marrow transplantation from an HLA-DR-mismatched donor in the host-versus-graft (HVG) direction with myeloablative conditioning. Neutrophil engraftment was achieved and complete donor chimera was obtained on days 21 and 29 after transplantation, respectively. Subsequently, with delayed blood cell recovery, continuous transfusion was needed to replace platelets. Read More

    [Durable remission attained with plasmapheresis and intravenous immunoglobulin therapy in a patient with acute exacerbation of GVHD-related myasthenia gravis].
    Rinsho Ketsueki 2018 ;59(5):480-484
    Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University.
    A 17-year-old male underwent a second bone marrow transplantation using a 6/8 allele HLA-matched unrelated donor. On day 100 after transplantation, steroid treatment for chronic graft-versus-host disease (GVHD) was started. On day 766, the patient experienced general fatigue, followed by double vision, ptosis, and dysphagia on day 810. Read More


    The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Hum Gene Ther Clin Dev 2018 Jun 5. Epub 2018 Jun 5.
    The Czech Academy of Sciences, Institute of Experimental Medicine, Prague, Czech Republic ;
    Advanced therapy medicinal products (ATMPs) represent a new generation of biopharmaceuticals that comprise gene therapy medicinal products (GTMPs), somatic cell therapy products (CTMPs), tissue engineered products (TEPs) and combined advanced therapy medicinal products (cATMPs). The joint effort of the academia-industry-regulatory triangle translated scientific progress into nine authorised ATMPs in the European Community. This notion holds promise for the whole field of ATMP therapies that have been increasingly evaluated in a number of clinical studies, also in the Czech Republic (CR). Read More

    Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children.
    Sci China Life Sci 2018 May 30. Epub 2018 May 30.
    Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
    To compare the efficacy of HLA6/6-matched haploidentical hematopoietic stem cell transplant (haplo-HSCT) with that of HLA3/6-matched HSCT in T-cell-replete transplants, we recruited 27 consecutive recipients from multiple centers who received HLA6/6-matched haplo-HSCT from a parent or child donor between February 2010 and May 2016. A matched-pair analysis was designed. For each recipient from the study cohort, two recipients were randomly selected from the control cohort and matched (according to patient age, patient sex, disease type, disease status, donor age, donor sex, and recipient-donor relationship). Read More

    Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection.
    Open Forum Infect Dis 2018 May 22;5(5):ofy090. Epub 2018 May 22.
    Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
    Background: Allogeneic hematopoietic cell transplantation (allo-HCT) in a CCR5∆32 homozygous donor resulted in HIV cure. Understanding how allo-HCT impacts the HIV reservoir will inform cure strategies.

    Methods: A 12-year-old with perinatally acquired, CCR5-tropic HIV and acute lymphoblastic leukemia underwent myeloablative conditioning and umbilical cord blood (UCB) transplantation from a CCR5∆32 homozygous donor. Read More

    Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.
    Front Immunol 2018 16;9:1087. Epub 2018 May 16.
    Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immunopharmacology of Education, Ministry of China, Anti-Inflammatory Immune Drugs Collaborative Innovation Center, Hefei, Anhui, China.
    Graft-versus-host disease (GVHD) is a serious and deadly complication of patients, who undergo hematopoietic stem cell transplantation (HSCT). Despite prophylactic treatment with immunosuppressive agents, 20-80% of recipients develop acute GVHD after HSCT. And the incidence rates of chronic GVHD range from 6 to 80%. Read More

    Protective Role of Myeloid Cells Expressing a G-CSF Receptor Polymorphism in an Induced Model of Lupus.
    Front Immunol 2018 9;9:1053. Epub 2018 May 9.
    Department of Pathology, Immunology, Laboratory Medicine, University of Florida Diabetes Institute, University of Florida, Gainesville, FL, United States.
    The genetic analysis of the lupus-prone NZM2410 mouse has identified a suppressor locus, , which confers resistance to spontaneous lupus in combination with NZM2410 susceptibility loci, or in the chronic graft-versus-host disease (cGVHD) induced model of lupus in the B6. congenic strain. The candidate gene for , the gene encoding the granulocyte colony-stimulating factor receptor (G-CSF-R/CD114), was validated when cGVHD was restored in B6. Read More

    Foxp3 T Regulatory Cells: Still Many Unanswered Questions-A Perspective After 20 Years of Study.
    Front Immunol 2018 15;9:1048. Epub 2018 May 15.
    Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
    T regulatory (Treg) cells were discovered more than 20 years ago and have remained a topic of intense investigation by immunologists. The initial doubts about their existence were dissipated by the discovery in 2003 of the lineage specific transcription factor Foxp3. In this article, I will discuss some of the questions that I believe still need to be answered before we will be able to fully apply Treg therapy to the clinic. Read More

    MicroRNA in T-Cell Development and T-Cell Mediated Acute Graft-Versus-Host Disease.
    Front Immunol 2018 7;9:992. Epub 2018 May 7.
    Institute for Molecular Medicine, Goethe-University Frankfurt, Frankfurt am Main, Germany.
    Acute graft-versus-host disease (GvHD) is still a major cause of treatment-related mortality after allogeneic stem cell transplantation. Allo-antigen recognition of donor T cells after transplantation account for the onset and persistence of this disease. MicroRNAs (miRNAs) are molecular regulators involved in numerous processes during T-cell development, homeostasis, and activation. Read More

    Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.
    Front Immunol 2018 7;9:984. Epub 2018 May 7.
    Immunology Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy.
    γδ T lymphocytes are potent effector cells, capable of efficiently killing tumor and leukemia cells. Their activation is mediated by γδ T-cell receptor (TCR) and by activating receptors shared with NK cells (e.g. Read More

    Aire Disruption Influences the Medullary Thymic Epithelial Cell Transcriptome and Interaction With Thymocytes.
    Front Immunol 2018 7;9:964. Epub 2018 May 7.
    Molecular Immunogenetics Group, Genetics, Ribeirão Preto Medical School, Universidade de São Paulo, São Paulo, Brazil.
    The function of medullary thymic epithelial cells (mTECs) is associated with thymocyte adhesion, which is crucial for the negative selection of autoreactive thymocytes in the thymus. This process represents the root of central tolerance of self-components and prevents the onset of autoimmune diseases. Since thymic epithelia correspond to an important target of donor T cells during the onset of chronic graft-vs-host-disease, mTEC-thymocyte adhesion may have implications for alloimmunity. Read More

    Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
    J Immunother 2018 Jul/Aug;41(6):306-311
    Department of Hematology, Xinqiao Hospital.
    Background: Reduced-intensity conditioning (RIC) regimens with low tolerable toxicities have been used for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the relapse rate by this treatment is high. Treatment of CD19 B-cell relapsed/refractory acute lymphoblastic leukemia (r/r ALL) with allogeneic chimeric antigen receptor-modified T (CAR-T) cells is safe and effective. Read More

    Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
    Ann Hematol 2018 Jun 2. Epub 2018 Jun 2.
    Division of Hematology, Saitama Medical University, Jichi Medical University, 1-847 Amanuma-cho Omiya-ku, Saitama, 330-8503, Japan.
    The optimal treatment strategy for gastrointestinal graft-versus-host disease (GI-GVHD) after allogeneic hematopoietic cell transplantation remains to be established. We retrospectively analyzed 68 cases of GI-GVHD at our institution between 2007 and 2017. The survival outcomes were significantly inferior in patients who did not respond to the first-line treatment (1-year overall survival 27. Read More

    1 OF 599